A New Pill for Stubborn High Blood Pressure: What Baxdrostat's FDA Approval Means for Patients
Hypertension shows up in almost every cardiology visit I do. Most of my patients with high blood pressure get to goal on one or two medications. About one in four don’t. That stubborn group, who keep running 150 over 90 despite a couple of well-chosen pills, has been waiting a long time for something genuinely new. On May 18, 2026 they got it. The FDA approved baxdrostat (brand name Baxfendy) as the first medication in a brand-new class for hypertension. I want to walk you through what this drug is, who it’s for, and what to think about if your blood pressure has been a problem.
Why blood pressure stalls on the medications we already have
For decades, the standard playbook for high blood pressure has been to start with a low-dose ACE inhibitor or ARB, add a thiazide diuretic, add a calcium channel blocker, and if that combination isn’t enough, add a fourth medication called spironolactone. Spironolactone works on a different problem than the first three. It blocks the receptor that a hormone called aldosterone binds to. Aldosterone is made by your adrenal glands, the small organs that sit on top of your kidneys, and it tells your kidneys to hold onto sodium and water. More sodium retained means more fluid in your blood vessels, which means higher pressure.
The trouble with spironolactone is that the receptor it blocks isn’t found only in the kidney. It’s also in places where it shouldn’t be blocked. Men taking spironolactone for resistant hypertension commonly develop breast tenderness or visible breast tissue enlargement (the medical term is gynecomastia). Women can develop menstrual irregularities. Testosterone can drop. For a lot of patients, the side effects make spironolactone hard to stay on, especially at the doses needed to keep blood pressure in range. So we’d find ourselves with patients whose blood pressure was still uncontrolled because the only fourth-line drug we had wasn’t tolerable.
This is the gap baxdrostat is built for.
What baxdrostat does differently
Baxdrostat is what we call an aldosterone synthase inhibitor. Rather than block the receptor that aldosterone binds to, it stops your adrenal glands from making aldosterone in the first place. The enzyme that produces aldosterone is called aldosterone synthase. Block the enzyme, and you cut aldosterone production at the source.
That sounds straightforward, but the chemistry is hard. Aldosterone synthase shares about 93 percent of its genetic code with another enzyme called cortisol synthase. Cortisol is the body’s main stress hormone, and you absolutely need it. Earlier attempts at this class of drug couldn’t tell the two enzymes apart, so they suppressed cortisol along with aldosterone and put patients at risk for adrenal insufficiency. Baxdrostat was engineered to bind aldosterone synthase more than a hundred times more strongly than it binds cortisol synthase. The result is targeted aldosterone suppression without touching your stress-hormone system.
Practically, this means baxdrostat gives us a way to lower aldosterone-driven blood pressure without the breast and sex-hormone side effects that hold spironolactone back. It’s a once-daily pill.
The trial that got it approved
The FDA approval was based on a Phase 3 trial called BaxHTN. It enrolled patients with uncontrolled or treatment-resistant hypertension, meaning their blood pressure was still above goal while taking at least two other antihypertensive medications. After 12 weeks, the 2 mg dose of baxdrostat lowered seated systolic blood pressure by 9.8 mmHg more than placebo. That’s a real number. For context, getting a patient from 150 systolic down to 140 systolic, on top of their existing regimen, cuts their stroke risk by roughly 20 percent over the following few years. A 10-point drop on top of existing therapy is the kind of move that changes outcomes.
The safety profile in the trial was clean. No surprises beyond what you’d expect from any aldosterone-lowering medication. Some patients had a small increase in potassium, which we monitor for routinely.
Who I think this is for
The patients most likely to benefit from baxdrostat are the ones whose blood pressure stays above 140/90 (or 130/80 if they have diabetes, kidney disease, or established heart disease) despite two or three well-chosen medications. That’s a group I see often. Some of them have what we call “primary aldosteronism,” which means their adrenal glands are making too much aldosterone for reasons we can sometimes identify. For those patients, an aldosterone-targeting drug is the logical next move. Many other patients with resistant hypertension don’t have obvious primary aldosteronism on labs but still respond well to drugs that lower aldosterone. They’re also strong candidates.
I want to be honest about three caveats.
Cost will be a barrier early on. Baxfendy is brand-new. Generic spironolactone costs almost nothing. Until insurance coverage settles in, baxdrostat is going to require prior authorizations and may carry meaningful out-of-pocket cost. For patients whose insurance pushes back, getting the drug means documenting an inadequate response or intolerance to spironolactone first.
We don’t yet have long-term cardiovascular outcomes data. The BaxHTN trial measured blood pressure changes over weeks to months. We know that lowering blood pressure prevents strokes and heart attacks in the long run, but the specific drug’s effect on heart attack and stroke rates over years is something we’ll learn as outcomes trials read out over the next few years.
Potassium needs monitoring. Anything that blocks the aldosterone pathway can raise potassium levels. We check this on routine labs before starting and at intervals after. It’s manageable, but it’s a reason your cardiologist or primary care doctor needs to be involved in the prescribing decision rather than starting it on your own.
What to do if your blood pressure has been a problem
If you’re well controlled on the medications you’re already taking, nothing changes for you. Stay on what’s working.
If you’ve been running high despite two or three medications, this is worth a conversation. Bring it up at your next visit. The questions worth asking: Am I a candidate for an aldosterone test? Should we try spironolactone first to see if my blood pressure responds to aldosterone targeting at all? If spironolactone doesn’t work or isn’t tolerated, would baxdrostat be a fit?
If you’ve stopped a blood pressure medication in the past because of side effects, this is also worth raising. Sometimes “intolerance” really means a specific drug class wasn’t right for you. Aldosterone synthase inhibition is a different mechanism than what you’ve probably tried, and the side-effect profile is different too.
Take a look at my hypertension guide if you’re newer to thinking about blood pressure as a category. If you’ve had clues that your high blood pressure might be coming from something specific beyond lifestyle and genetics, my secondary hypertension article walks through the workup. And if you’re already worried about kidney damage from years of borderline-controlled pressure, I wrote about that here.
My take
Baxdrostat is the first genuinely new mechanism in hypertension in a long time. That alone is worth paying attention to. The 9.8 mmHg drop on top of existing therapy is meaningful, and the cleaner side-effect profile compared to spironolactone solves a real problem in my practice. I expect to be writing more prescriptions for it once it’s available in early June, especially for patients who’ve struggled with spironolactone or whose blood pressure stays high despite a thoughtful regimen.
It won’t replace what already works. Patients well-controlled on a standard combination of an ACE inhibitor, a diuretic, and a calcium channel blocker don’t need to switch. Patients whose blood pressure has been the problem we couldn’t fully solve, though, now have a real new option. That’s good news.